InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,476.18
(
0.05%
)
US TECH 100
19,300.80
(
0.22%
)
Dow Jones
39,128.10
(
-0.02%
)
Brent Oil
84.53
(
-0.56%
)
Bitcoin
63,723.82
(
-1.70%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: ariadndndough post# 32226

Monday, 07/15/2013 7:58:17 AM

Monday, July 15, 2013 7:58:17 AM

Post# of 80490
Saw that...expands Pona's activity against other targets...

Check out Table 12 for comparison of GI50 in all four FGFR types for 7 different cancer indications against the competition: Cediranib, Dovitinib, Nintedanib, and Brivanib.

FGFR chapter for Pona just beginning.


Footnote-
IC50 is the maximal concentration of drug to cause 50% inhibition of biological activity of cancer cells.
GI50 is the concentration of drug to cause 50% reduction in proliferation of cancer cells i.e. growth.
ED50 refers to the dose of the drug which causes 50% response in a biological system or which treats effectively 50% population.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up